The treatment of hyperparathyroidism includes all interventions intended to correct excessive biological signalling by PTH and its consequences for calcium and phosphate homeostasis, bone remodelling and the risk of renal and cardiovascular complications. The term “hyperparathyroidism” does not identify a single disease, but rather a common pathophysiological condition shared by different disorders, including primary hyperparathyroidism, caused by autonomous parathyroid secretion, secondary hyperparathyroidism, which is an adaptive response typically associated with chronic kidney disease, tertiary hyperparathyroidism, caused by autonomy following chronic stimulation and often occurring after transplantation, and rarer forms related to medicines, vitamin D deficiency or genetic abnormalities. Treatment therefore cannot be reduced to a single medicine: it depends on the cause, severity, target-organ risk profile and clinical setting.
The aim is not to “lower PTH” as an end in itself, but to restore a balance in which parathyroid signalling no longer causes hypercalcaemia, hypophosphataemia or hyperphosphataemia, loss of bone mass, nephrolithiasis, nephrocalcinosis, neuropsychiatric symptoms and, in patients with chronic kidney disease, progression of the mineral disorder and vascular calcification. In practical terms, the paradigm changes according to the clinical scenario: in primary hyperparathyroidism, definitive treatment is often surgical, whereas in secondary hyperparathyroidism the approach is mainly medical and integrated with the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD), with parathyroidectomy reserved for refractory or complicated cases. The principles described here form the common basis linking pathophysiology, pharmacological treatment, surgical indications and follow-up, enabling consistent and safe decisions in both the short and long term.
PTH is a rapid regulator of ionised calcium and, in an integrated manner, of phosphate availability and renal calcitriol production. In primary hyperparathyroidism, the fundamental abnormality is autonomous secretion: one or more parathyroid glands produce PTH inappropriately in relation to serum calcium, causing increased bone resorption, enhanced tubular calcium reabsorption and increased calcitriol production, with consequent hypercalcaemia and, frequently, hypophosphataemia. In secondary hyperparathyroidism, the underlying logic is reversed: elevated PTH secretion is an adaptive response to calcitriol deficiency, phosphate retention and calcium abnormalities in chronic kidney disease, with progressive parathyroid hyperplasia and, in advanced cases, loss of precise control of the calcium-sensing receptor set-point.
Treatment objectives must therefore be defined differently in each setting. In primary hyperparathyroidism, the objective is to prevent target-organ damage caused by hypercalcaemia and increased bone turnover, reduce the risk of fractures, nephrolithiasis and renal decline, and improve symptoms when present. In CKD-related secondary hyperparathyroidism, the objective is to control excess PTH while avoiding both persistent high bone turnover and excessive suppression, which would promote low-turnover bone disease, while maintaining calcium and phosphate within ranges associated with the lowest possible risk of vascular calcification and systemic complications. In tertiary hyperparathyroidism, the objective is to interrupt established autonomy that may sustain post-transplant hypercalcaemia, with adverse effects on bone, the transplanted kidney and cardiovascular risk.
A crucial point, particularly in CKD, is that PTH is an imperfect biomarker: therapeutic decisions must integrate trends over time, calcium and phosphate values, current treatment, fracture history, signs of bone disease and conditions that amplify the mineral disorder. In clinical practice, the endocrine rationale always requires differentiation between appropriately elevated PTH and pathologically elevated PTH, and between hyperparathyroidism requiring correction of the underlying cause, hyperparathyroidism requiring pharmacological modulation and hyperparathyroidism requiring surgery because of autonomy or complications.
Finally, the treatment objective must also be expressed in terms of safety: preventing hypercalcaemic crises, avoiding iatrogenic hypocalcaemia caused by excessively aggressive treatment and reducing the likelihood of renal and vascular complications. Treatment of hyperparathyroidism is therefore a discipline of clinical precision: the same final PTH pathway, but different objectives and different therapeutic tools selected according to the cause and risk profile.
Medical treatment of hyperparathyroidism uses interventions that act at several levels of the underlying pathophysiology. Correction of vitamin D deficiency is a cross-cutting intervention because 25(OH)D deficiency increases PTH secretion and amplifies instability of the mineral set-point. In primary hyperparathyroidism, cautious correction of vitamin D deficiency may reduce PTH and improve calcium balance without necessarily worsening hypercalcaemia when appropriately monitored. In secondary hyperparathyroidism, vitamin D correction is part of the CKD-MBD management strategy, together with phosphate control and, when indicated, the use of active forms or analogues of vitamin D. Calcitriol and active analogues suppress PTH but, by increasing intestinal calcium and phosphate absorption, may promote hypercalcaemia and hyperphosphataemia, particularly when renal function is impaired and the ability to excrete phosphate is reduced.
Calcimimetics are a distinctive pharmacological tool because they act on the calcium-sensing receptor (CaSR) of parathyroid cells, increasing its sensitivity to extracellular calcium and reducing PTH secretion. In CKD-related secondary hyperparathyroidism, calcimimetics are used to lower PTH, often with favourable effects on serum calcium and phosphate, although their main risk is hypocalcaemia, together with gastrointestinal symptoms or, in the case of intravenous formulations, other effects related to the route of administration. In primary hyperparathyroidism, cinacalcet may be used in selected settings as bridging treatment or as an alternative when surgery is not possible or must be postponed, with the primary aim of controlling hypercalcaemia rather than correcting the bone mineral density deficit.
For the skeletal component of primary hyperparathyroidism, particularly in patients who are not candidates for surgery or who are awaiting an operation, antiresorptive treatments such as bisphosphonates may increase bone mineral density and reduce the effect of high turnover on fracture risk. In this setting, antiresorptive treatment does not cure PTH autonomy, but protects the skeletal target organ. The choice between an agent that lowers serum calcium and PTH, such as a calcimimetic, and an agent that improves bone density, such as a bisphosphonate, reflects a clinical principle of priority: controlling hypercalcaemia, protecting the skeleton or achieving both aims through a combined strategy, always with careful monitoring and a clearly defined objective.
In secondary hyperparathyroidism, in addition to calcimimetics and active vitamin D, phosphate management through dietary restriction and phosphate binders is an integral part of treatment because phosphate retention is a central driver of elevated PTH and vascular complications. In summary, the pharmacology of hyperparathyroidism is not simply a list of compounds, but an endocrine and nephrological therapeutic toolkit that must be used consistently with the cause, calcium and phosphate values and the target organs involved.
In primary hyperparathyroidism, parathyroidectomy is the only definitive treatment because it removes the autonomous source of PTH. Surgical societies and international workshops emphasise that surgery is indicated in all symptomatic patients and should be considered in most asymptomatic patients when there is evidence of target-organ involvement or increased risk, such as significant hypercalcaemia, reduced bone mineral density or fractures, nephrolithiasis or nephrocalcinosis, and impaired renal function. In this setting, treatment planning begins with a question: is the objective definitive cure through surgery, or temporary or long-term medical control because surgery is not possible, is not available within an appropriate timeframe or is declined?
When a non-surgical strategy is adopted in primary hyperparathyroidism, the logical sequence is constructed around the main risk drivers. If the predominant problem is hypercalcaemia, cinacalcet may lower serum calcium and reduce symptoms, making the waiting period safer or stabilising frail patients. If the predominant problem is skeletal fragility, the strategy may include bisphosphonates to improve bone density, with or without a calcimimetic depending on serum calcium. Correction of vitamin D deficiency and optimisation of dietary calcium intake must be integrated cautiously because excessive calcium restriction may paradoxically increase PTH and worsen skeletal balance, whereas excessive intake may promote hypercalciuria and stone risk. Correct planning therefore requires construction of a balance that does not amplify the disease through intuitive but pathophysiologically unfavourable interventions.
In CKD-related secondary hyperparathyroidism, the initial choice is not between surgery and medical treatment, but between different medical strategies, with parathyroidectomy considered only in refractory cases. The usual sequence begins with correction of the underlying drivers: control of phosphate, correction of vitamin D deficiency and optimisation of calcium, followed by the introduction or adjustment of active vitamin D or its analogues and, when appropriate, calcimimetics. The initial choice between active vitamin D and a calcimimetic, or their combination, depends mainly on serum calcium and phosphate and on the PTH trend. In dialysis patients with elevated or rising PTH, international guidelines indicate that calcitriol, vitamin D analogues, calcimimetics or a combination may be used to lower PTH, with the initial selection guided by the calcium and phosphate profile.
In tertiary hyperparathyroidism, often occurring after kidney transplantation, the strategy is based on recognising autonomy: when hyperparathyroidism persists with hypercalcaemia and elevated PTH, temporary medical options, including calcimimetics, may be considered, but parathyroidectomy remains an important option in the presence of significant autonomy, complications or failure of medical control. In every setting, correct treatment planning requires a sequential method: define the cause, identify target organs and risk, select the intervention that acts on the predominant driver and plan follow-up capable of measuring success and preventing iatrogenic harm.
Monitoring of hyperparathyroidism treatment must be guided by the objective and the phase of treatment. In primary hyperparathyroidism managed surgically, preoperative monitoring documents disease severity and target-organ involvement, whereas postoperative monitoring aims to identify transient hypocalcaemia, hungry bone syndrome and progressive normalisation of calcium and PTH. In primary hyperparathyroidism managed medically, monitoring must assess control of serum calcium, stability of PTH, risk of hypercalciuria, renal-function trends and skeletal trajectory, including densitometry and longitudinal fracture-risk assessment. From this perspective, control of serum calcium alone is insufficient: a patient whose calcium has been lowered by a calcimimetic may retain a high skeletal risk if turnover remains elevated and skeletal protection has not been addressed.
In CKD-related secondary hyperparathyroidism, monitoring is intrinsically multiparametric and longitudinal. Decisions are based on trends in PTH, serum calcium and phosphate, with alkaline phosphatase incorporated as an indirect marker of bone turnover and, in selected cases, imaging or specialist assessment of calcification risk. Interpretation must avoid two opposing errors: pursuing a single PTH value with aggressive therapies that cause hypocalcaemia or hyperphosphataemia, or undertreating a rising PTH level that reflects progressive hyperplasia and a risk of high-turnover osteodystrophy. In this population, dialysis modality, calcium delivery through the dialysate, use of phosphate binders and vitamin therapy also substantially influence the mineral profile and must form part of the clinical interpretation.
When calcimimetics are used, monitoring must include particular attention to hypocalcaemia, which may be asymptomatic or symptomatic and, if not recognised, may lead to treatment interruption and fluctuations in PTH. When vitamin D analogues are used, monitoring must consider the risk of hypercalcaemia and hyperphosphataemia, particularly in the presence of phosphate retention. When bisphosphonates are used in primary hyperparathyroidism, skeletal monitoring must be integrated with renal-function assessment and the risk of hypocalcaemia in predisposed settings. Effective monitoring is therefore not merely frequent, but consistent with the therapeutic intervention and capable of measuring both benefit and risk over the long term.
A cross-cutting aspect is the standardisation of assessments and their comparability over time. Changes in diet, supplements, concomitant treatment and hydration status may alter serum calcium and urinary calcium and must be identified as part of follow-up. Treatment of hyperparathyroidism is often chronic or otherwise prolonged, so monitoring must be structured as a pathway rather than as a sequence of isolated values.
The response to hyperparathyroidism treatment is influenced by numerous variables that, if not recognised, may produce apparent treatment failure or iatrogenic harm. In primary hyperparathyroidism, serum calcium may be affected by hydration status, calcium intake, thiazide diuretics, lithium and other medicines that alter the calcium set-point or renal calcium handling. Lithium, in particular, may increase the CaSR set-point and promote hyperparathyroidism and hypercalcaemia, with specific therapeutic implications. Severe vitamin D deficiency may also mask the severity of primary hyperparathyroidism through a less pronounced elevation of serum calcium and a very high PTH concentration. Correction of vitamin D deficiency may reveal a rise in serum calcium, requiring careful monitoring and a planned strategy.
In CKD-related secondary hyperparathyroidism, interactions among phosphate, vitamin D, calcimimetics and phosphate binders account for much of the variability in response. Changes in dialysis, dialysate composition, protein intake and adherence to phosphate binders may rapidly alter serum phosphate and, consequently, PTH. In addition, the risk of calcimimetic-induced hypocalcaemia may require adjustment of dialysate composition or vitamin therapy, and these adjustments may themselves influence phosphate. The response is therefore not linear and requires integrated interpretation of all variables involved in CKD-MBD.
In post-transplant tertiary hyperparathyroidism, transplanted kidney function, immunosuppressive treatment and the dynamics of post-uraemic skeletal recovery influence the response. Persistent hyperparathyroidism may sustain hypercalcaemia and hypophosphataemia, with potential effects on graft function and stone risk. In this setting, cinacalcet may correct hypercalcaemia and hypophosphataemia in selected patients, but definition of its long-term role must consider the possibility of stable autonomy and the need for a definitive surgical solution in appropriate cases.
Finally, comorbidities such as osteoporosis, fall risk, diabetes, cardiovascular disease and frailty influence therapeutic priorities. In primary hyperparathyroidism, for example, a patient with a vertebral fracture and moderate hypercalcaemia may require a strategy prioritising skeletal benefit and definitive cure. In secondary hyperparathyroidism, a patient with vascular calcification and persistent hyperphosphataemia requires stricter phosphate control and cautious selection of interventions that increase calcium and phosphate. Identification of interactions and comorbidities is therefore an essential component of treatment because it determines the choice of the most effective and safest intervention.
Treatment of hyperparathyroidism requires important adaptations in special settings because tolerance of the mineral load and the risk-benefit balance change. During pregnancy, primary hyperparathyroidism, although rare, is clinically relevant because maternal hypercalcaemia may be associated with maternal and fetal complications, and management must balance maternal safety, obstetric risk and the timing of possible surgery. In this setting, parathyroidectomy may be considered when disease severity requires it, whereas medical treatment must be selected with extreme caution, taking into account the limited evidence and the safety profile of the available treatments.
In children and adolescents, primary hyperparathyroidism is frequently associated with genetic syndromes or rare conditions, and treatment requires a specialist pathway that includes genetic assessment when appropriate and a strategy that protects growth and skeletal development. Surgery in experienced centres has a central role because it provides definitive cure and reduces the lifelong burden of skeletal and renal risk. In secondary hyperparathyroidism occurring in paediatric CKD, CKD-MBD management also has major implications for growth, development and the risk of skeletal deformities.
In older adults and frail patients, the clinical manifestations of primary hyperparathyroidism may be more subtle and overlap with comorbidities, but the risks of fractures, falls and cardiovascular complications often make effective control a priority. Surgical risk must be assessed carefully in these patients, although surgery performed by experienced teams may be highly effective. When medical treatment is selected, monitoring must be more intensive to prevent fluctuations in serum calcium and reduce the risks of dehydration and worsening renal function.
In patients with chronic kidney disease, particularly those receiving dialysis, the population is intrinsically special because treatment of secondary hyperparathyroidism occurs within a network of determinants that includes sodium-volume balance, inflammation, malnutrition, calcification and frailty. Every pharmacological adjustment must therefore be interpreted within the context of CKD-MBD, with particular attention to its consequences for calcium and phosphate and its effect on vascular calcification risk. In special settings, the underlying treatment principles do not change, but their application becomes more closely personalised and safety-oriented.
Advanced strategies for hyperparathyroidism are those that address autonomy or treatment refractoriness. In primary hyperparathyroidism, parathyroidectomy is not only curative but often cost-effective over the long term, particularly when target-organ involvement is present. Surgery performed in experienced centres provides stable control of serum calcium and progressive improvement in skeletal status, with particular attention to multiglandular disease and genetic syndromes. In patients who cannot undergo surgery, an advanced strategy involves combining interventions with different objectives, such as a calcimimetic to control hypercalcaemia and an antiresorptive agent to protect the skeleton, while maintaining cautious correction of vitamin D deficiency and careful management of urinary calcium and stone risk.
In CKD-related secondary hyperparathyroidism, refractoriness is characterised by very high and progressively rising PTH despite phosphate control, treatment with active vitamin D and calcimimetics, often accompanied by clinical or biochemical signs of high-turnover osteodystrophy and progressive calcification. In these cases, parathyroidectomy becomes a fundamental advanced strategy. Its indication is based on the presence of autonomous hyperplasia and the clinical impact of the disease, with the objective of reducing PTH and improving control of the mineral profile, while recognising the risk of hungry bone syndrome and postoperative hypocalcaemia, which require an intensive postoperative management plan. Advanced treatment also includes pharmacological combinations in dialysis, such as calcimimetics combined with active vitamin D to balance PTH suppression with calcium and phosphate control, always according to a strategy guided by mineral parameters and individual risk.
In post-transplant tertiary hyperparathyroidism, the advanced strategy requires differentiation between a phase of slow regression of hyperplasia and true persistent autonomy. Cinacalcet may be used to control hypercalcaemia and phosphate abnormalities in selected patients, but surgery retains an important role when autonomy is marked or complicated because it provides a definitive solution and reduces prolonged exposure to hypercalcaemia. In this setting, the strategy must also include management of post-transplant skeletal health, which is often complex because of previous uraemia, glucocorticoid treatment and recovery of bone turnover.
Advanced strategies therefore transform reactive management into a definitive or stabilising pathway: surgery when the autonomous source predominates, pharmacological combinations when the pathophysiology requires a balance among calcium, phosphate and PTH, and follow-up that genuinely measures benefit in the target organs.
The safety of hyperparathyroidism treatment depends on the ability to avoid two symmetrical errors: allowing prolonged PTH excess to damage bone and kidney, or suppressing or correcting it too aggressively and inducing hypocalcaemia and instability of the mineral profile. In primary hyperparathyroidism, the main risk of medical treatment with calcimimetics is relative hypocalcaemia and the onset of symptoms, whereas the risk of underestimating hypercalcaemia is progression of stone risk and deterioration of renal function. Unplanned correction of vitamin D deficiency in the presence of significant autonomy may also increase serum calcium, making careful monitoring and a clear strategy necessary.
In CKD-related secondary hyperparathyroidism, safety is dominated by the balance between calcium and phosphate. Calcimimetics may reduce PTH and serum calcium but cause hypocalcaemia, which may require adjustment of active vitamin D treatment or dialysate composition. Vitamin D analogues may reduce PTH but increase serum calcium and phosphate, thereby increasing calcification risk. In this setting, prevention of iatrogenic harm depends on selecting initial treatment according to calcium and phosphate and using combinations when their effects need to be balanced. Effective treatment that ignores serum phosphate may lower PTH while increasing vascular risk, whereas treatment that lowers phosphate but causes hypocalcaemia may precipitate symptoms and lead to treatment interruption.
Surgical safety requires specific attention to the postoperative period. After parathyroidectomy, particularly in CKD or severe hyperparathyroidism, the risk of hungry bone syndrome requires intensive monitoring and calcium and vitamin D supplementation to prevent severe hypocalcaemia. In primary hyperparathyroidism, identification of multiglandular disease and management of the risk of postoperative hypoparathyroidism require experience and follow-up. In post-transplant tertiary hyperparathyroidism, an abrupt reduction in PTH may also cause significant mineral shifts that must be anticipated and managed.
Ultimately, treatment of hyperparathyroidism is safe when it is guided by explicit and measurable objectives and when the clinician anticipates the predictable consequences of every intervention on calcium, phosphate and bone turnover. Prevention of iatrogenic harm is not a separate component, but the condition that makes long-term treatment sustainable.
Many patients with hyperparathyroidism, particularly CKD-related secondary hyperparathyroidism, undergo complex treatment that includes phosphate binders, vitamin D, calcimimetics and dietary changes. Adherence is therefore a genuine determinant of effectiveness. In secondary hyperparathyroidism, poor adherence to phosphate binders or dietary restriction may sustain hyperphosphataemia and cause PTH to remain elevated or continue to rise, prompting pharmacological escalation that increases the risk of hypocalcaemia or hypercalcaemia without addressing the main driver. Therapeutic education must therefore explain the pathophysiological relationship among phosphate, PTH and vascular risk because understanding the reason for treatment increases the likelihood of adherence.
In primary hyperparathyroidism managed medically, adherence mainly concerns regular use of treatment and consistency of behaviours that influence serum calcium and urinary calcium. Patients must understand that hydration, calcium and vitamin D intake and concomitant medicines may alter the mineral profile. They must also recognise signs of deterioration or iatrogenic harm, such as symptoms of hypercalcaemia or hypocalcaemia, so that assessment can be brought forward and complications prevented. In this setting, quality of life is not a secondary parameter, but an indicator of stability: fluctuations in the mineral profile and intermittent symptoms reduce physical performance, sleep quality and neurocognitive well-being.
Management of expectations is a critical element. In primary hyperparathyroidism, many symptoms are non-specific and may persist even after biochemical control, so therapeutic escalation based solely on symptoms that have not been adequately contextualised may cause iatrogenic harm. In secondary hyperparathyroidism, patients may perceive treatment as excessively burdensome and reduce adherence, thereby worsening control. Effective follow-up must therefore integrate education, carefully considered simplification of treatment regimens when possible and clear communication of objectives and warning signs.
Finally, quality of life may improve substantially when treatment genuinely reduces complications: control of phosphate and PTH in secondary hyperparathyroidism reduces pruritus, bone pain and instability, whereas definitive cure in primary hyperparathyroidism may improve symptoms, reduce fracture risk and prevent recurrent kidney stones. Treatment of hyperparathyroidism becomes sustainable when the patient and clinician share simple rules and a common objective: biochemical stability, target-organ protection and reduction of long-term risk.